Analysts expect that ContraFect Corp (NASDAQ:CFRX) will announce ($0.33) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for ContraFect’s earnings. ContraFect posted earnings per share of ($0.90) in the same quarter last year, which would suggest a positive year-over-year growth rate of 63.3%. The business is expected to report its next earnings results on Friday, August 14th.
According to Zacks, analysts expect that ContraFect will report full year earnings of ($1.42) per share for the current fiscal year, with EPS estimates ranging from ($1.79) to ($1.19). For the next year, analysts forecast that the company will post earnings of ($1.74) per share, with EPS estimates ranging from ($2.50) to ($1.13). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that follow ContraFect.
ContraFect (NASDAQ:CFRX) last posted its quarterly earnings data on Friday, May 15th. The biotechnology company reported ($0.49) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.59) by $0.10.
A number of analysts recently weighed in on the stock. Mizuho assumed coverage on shares of ContraFect in a report on Tuesday, June 9th. They issued a “buy” rating and a $12.00 price objective on the stock. ValuEngine raised shares of ContraFect from a “sell” rating to a “hold” rating in a report on Thursday, April 2nd. Maxim Group reiterated a “buy” rating and issued a $22.00 target price on shares of ContraFect in a research report on Thursday, March 19th. Cantor Fitzgerald began coverage on shares of ContraFect in a research report on Monday, June 8th. They issued an “overweight” rating and a $15.00 target price for the company. Finally, Chardan Capital reiterated a “buy” rating on shares of ContraFect in a research report on Sunday, June 7th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $16.00.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC bought a new position in shares of ContraFect during the 1st quarter valued at about $76,000. Spark Investment Management LLC bought a new position in shares of ContraFect during the 1st quarter valued at about $84,000. Squarepoint Ops LLC bought a new position in shares of ContraFect during the 1st quarter valued at about $126,000. Morgan Stanley bought a new position in shares of ContraFect during the 1st quarter valued at about $285,000. Finally, Trellus Management Company LLC boosted its position in shares of ContraFect by 12.3% during the 4th quarter. Trellus Management Company LLC now owns 600,000 shares of the biotechnology company’s stock valued at $372,000 after purchasing an additional 65,882 shares in the last quarter. Hedge funds and other institutional investors own 37.27% of the company’s stock.
Shares of CFRX stock traded down $0.48 during trading hours on Tuesday, reaching $5.86. The stock had a trading volume of 18,666 shares, compared to its average volume of 512,089. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.50 and a quick ratio of 2.50. ContraFect has a twelve month low of $2.69 and a twelve month high of $13.40. The firm has a 50-day simple moving average of $6.15 and a 200-day simple moving average of $5.59. The firm has a market capitalization of $106.86 million, a PE ratio of -1.77 and a beta of 1.08.
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Featured Story: Overbought
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.